Skip to main content

Mental Health

At Boehringer Ingelheim Mental Health, we are redefining mental health to enable people to thrive. We link behavior to the underlying neurobiology to develop targeted therapies that can ease the burden of these conditions, not just the symptoms. By combining traditional treatment approaches with new and innovative approaches and technologies, we will enable those with mental health conditions such as schizophrenia, borderline personality disorder or depression to create more meaningful connections to their lives, loved ones and society. Boehringer Ingelheim has a rich pipeline in all phases of development.

young-man-schizo
Mental disorder

Schizophrenia

Schizophrenia is characterized by three symptom domains and affects ~1% of global population. First and mostly known are the positive symptoms like hallucinations and delusions, secondly are negative symptoms like reduced emotion and lack of motivation and the third symptom domain is cognitive impairment like a poor memory or disorganized thinking. While there are already many drugs for treating positive symptoms, there is a significant unmet medical need for effective treatments for negative and cognitive symptoms.

Read more